Pituitary adenylate cyclase-activating polypeptide (PACAP) is an intraislet neuropeptide and shares insulinotropic and insulinsensitizing properties with glucagon-like peptide-1 (GLP-1); however, the pathophysiological significance of PACAP in diabetes remains largely unknown. To assess this, we crossed our recently developed transgenic mice overexpressing PACAP in pancreatic ␤-cells (Tg/ϩ), with lethal yellow agouti (KKA y ) mice (A y /ϩ), a genetic model for obesity-diabetes, and examined the metabolic and morphological phenotypes of F 1 animals. Tg/ϩ mice with the A y allele (Tg/ϩ:A y /ϩ) developed maturity-onset obesity and diabetes associated with hyperglycemia, hyperlipidemia, and hyperphagia, similar to those of A y /ϩ mice, but hyperinsulinemia was significantly ameliorated in Tg/ϩ:A y /ϩ mice. Although A y /ϩ mice exhibited a marked increase in islet mass resulting from hyperplasia and hypertrophy, this increase was significantly attenuated in Tg/ϩ:A y /ϩ mice. Size frequency distribution analysis revealed that the very large islets comprising one-fourth of islets of A y /ϩ mice were selectively reduced in Tg/ϩ:A y /ϩ mice. Because functional defects have been demonstrated in the large islets of obese animal models, together these findings suggest that PACAP regulates hyperinsulinemia and the abnormal increase in islet mass that occurs during the diabetic process.
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PACAP, which exists in two molecular forms, either with 27 (PACAP27) or 38 (PACAP38) amino acid residues, belongs to the vasoactive intestinal polypeptide/secretin/glucagon superfamily (Arimura, 1998; Vaudry et al., 2000) . Some members of this group, such as the gastrointestinal hormones glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide, stimulate ␤-cell growth, differentiation, and cell survival, in addition to their well documented nutrient-stimulated secretion of insulin (so-called "incretin effect") (Kieffer and Habener, 1999; Pospisilik et al., 2003) . GLP-1 and glucose-dependent insulinotropic polypeptide are secreted postprandially from the L-cells of the lower small intestine and from the K-cells of the upper small intestine, respectively, and released into the circulatory system. In comparison, PACAP is a neuropeptide in pancreatic islets, where it may act as a parasympathetic and sensory neurotransmitter, and stimulate secretion of insulin in a glucosedependent manner (Kieffer and Habener, 1999; Sherwood et al., 2000; Filipsson et al., 2001 ). In addition, PACAP has been shown to be expressed in islet ␤-cells (Yada et al., 1997; Portela-Gomes et al., 2003) . PACAP stimulates insulin secretion from insulin-secreting ␤-cell lines (Klinteberg et al., 1996; Straub and Sharp, 1996) , isolated pancreas (Yokota et al., 1993; Yada et al., 1994; Bertrand et al., 1996) , and intact animals (Fridolf et al., 1992) . There is recent evidence to suggest that PACAP exerts not only insulinotropic effects but also insulin-sensitizing properties like GLP-1. Yada et al. (2000) showed that intraperitoneal administration of PACAP reduces blood glucose in GK rats and mice on a high-fat diet. PACAP also enhances insulin-induced glucose uptake in 3T3-L1 adipocytes (Nakata et al., 1999) . These findings implicate a potential therapeutic role for PACAP in diabetes.
ZAC/PLAGL1, the products that regulate both apoptosis and cell cycle arrest, as well as a transcriptional regulator of the type 1 PACAP receptor (Ciani et al., 1999) , are a strong candidate gene for transient neonatal diabetes (Kamiya et al., 2000) . In addition, a genome-wide linkage study revealed a connection between chromosome 18p11, the site of the human PACAP gene (Hosoya et al., 1992) , and a susceptibility locus for type 2 diabetes (Parker et al., 2001 ). These findings imply that perturbation of PACAP signaling is involved in the pathogenesis of diabetes.
The plethora of peripheral and central effects of PACAP upon whole-body glucose metabolism includes the stimulation of insulin, glucagon (Fridolf et al., 1992; Filipsson et al., 2001) , and epinephrine (Hamelink et al., 2002) secretion; hormonal regulation of lipid and carbohydrate metabolism (Gray et al., 2001) ; suppression of appetite (Mizuno et al., 1998) ; and influence on higher brain functions, including psychomotor activity . This wide range of effects makes it difficult to determine the precise role of PACAP in both the regulation of glucose homeostasis and development of diabetes. In addition, identification of the mechanisms underlying the effects of PACAP in pancreatic islets has been hampered by a lack of suitable low-molecular-weight PACAP antagonists.
As an approach to understanding the physiological and pathophysiological significance of PACAP in the pancreas, we have recently generated transgenic mice overexpressing PACAP in islet ␤-cells under the control of human insulin promoter (Tg/ϩ mice) (Yamamoto et al., 2003) . Tg/ϩ mice are normoglycemic and normoinsulinemic under basal conditions. Although glucose homeostasis was maintained, Tg/ϩ mice showed a greater acute insulin response to glucose compared with nontransgenic wild-type (ϩ/ϩ) mice. Also, streptozotocin-induced increases in plasma glucose were attenuated in Tg/ϩ mice. Notably, streptozotocin-treated Tg/ϩ mice exhibited an increase in 5-bromo-2-deoxyuridine-positive ␤-cells, but without any change in the number of terminal deoxynucleotidyl transferase dUTP nick-end labelingpositive apoptotic cells. Morphometric analysis revealed that total islet mass increased in 12-month-old transgenic mice. In sharp contrast, PACAP-deficient mice ) exhibited significantly impaired glucose-induced insulin secretion .
These observations suggest that, in addition to its islet function required for a normal glucose-stimulated insulin secretion, PACAP has a protective role against type 1 diabetes from islet degeneration associated with streptozotocin administration, and long-term effects on islet ␤-cell mass and function. These findings motivated us to determine the role of PACAP in the development of type 2 diabetes, particularly in the regulation of islet mass in vivo. In the present study, we performed genetic crosses between Tg/ϩ and lethal yellow agouti (KKAy) mice (Ay/ ϩ), a mouse model of type 2 diabetes characterized by obesity, hyperlipidemia, insulin resistance, and hyperglycemia (Leibel et al., 1997) , and examined the metabolic and morphological phenotypes of F1 animals.
Materials and Methods
Animals. The generation of mice overexpressing PACAP specifically in the pancreatic islets (Tg/ϩ) has been reported previously (Yamamoto et al., 2003) . The male KKA y mice (A y /ϩ), in which the A y gene had been transferred into the original Japanese KK strain (Japan CLEA, Tokyo, Japan), were crossed with female Tg/ϩ mice with a C57BL/6J background to produce F 1 offspring. For genotyping, tail DNA was analyzed by the polymerase chain reaction using the following PACAP gene exon specific primers: exon 3, 5Ј-AGA AGA CGA GGC TTA CGA CCA G-3Ј (sense) and exon 4, 5Ј-ACG ACC GAC TGC AGG TAC TTC-3Ј (antisense). Four genotypes of F 1 mice (Tg/ϩ:A y /ϩ, Tg/ϩ, A y /ϩ, and ϩ/ϩ) with a C57BL/6J and KK hybrid background were obtained. Male F 1 mice with the four genotypes were used in the present study. Mice were housed in a temperature-, humidity-, and light-controlled room with a 12-h light/12-h dark cycle (lights on from 8:00 AM to 8:00 PM) and allowed free access to water and food (CMF, 369 kcal/100 g; Oriental Yeast Co. Ltd., Tokyo, Japan). All animal care and handling procedures were approved by the Institutional Animal Care and Use Committee of Osaka University.
Analysis of Pancreatic PACAP Content. The pancreatic PACAP content was determined as described previously (Tamakawa et al., 1998 ) with a few modifications. Each of pancreata was weighed, boiled in 0.5 M acetic acid for 10 min, homogenized using Polytron, and then boiled for another 10 min. After centrifugation (2000 g; 10 min), the supernatant was applied to a Sep-Pak C-18 cartridge (Waters, Milford, MA), which was washed with water and then eluted with 60% acetonitrile-distilled water containing 0.1% trifluoroacetic acid. The eluate was lyophilized, and the PACAP content was measured by a radioimmunoassay using a commercial kit (Peninsula Laboratories, Belmont, CA).
Measurement of Food Intake. The F 1 mice were maintained in individual metabolic cages, and a food tray was placed in their cage. The cumulative food intake was measured by weighing the residual food in the tray after 2 weeks.
Measurement of Blood Glucose, Insulin, and Triglyceride Concentrations. Blood was sampled from the tail vein of fed mice from 9:00 to 11:00 AM. The plasma glucose, insulin, and triglyceride concentrations were measured using the Glucose CII-test (Wako Pure Chemicals, Osaka, Japan), a Sensitive Rat Insulin RIA kit (Linco Research, Inc., St. Charles, MO), and a Triglyceride INT kit (Sigma-Aldrich, Tokyo, Japan), respectively.
Glucose and Insulin Tolerance Test. For the insulin tolerance test, male F 1 mice were injected intraperitoneally with 0.5 or 2 U/kg porcine insulin (Sigma-Aldrich) after a 2-hour fast. For the glucose tolerance test, mice were orally injected with 2 mg/g glucose after a 14-h fast. Blood was sampled from the tail vein just before (time 0) and at 10, 30, 60, 90, and 120 min after the injection. The plasma glucose and insulin concentrations were determined as described above.
Immunohistochemistry and Quantitative Pancreatic Histomorphometry. The pancreas was carefully removed from each F 1 mouse. After weighing, each pancreas was immediately fixed in a 4% paraformaldehyde phosphate-buffered saline (PBS) solution and left overnight. It was then successively immersed in a 30% sucrose PBS solution for 48 h, frozen under nitrogen fumes, and stored at Ϫ80°C until sectioning. Serial sections (14 m in thickness) were obtained from each pancreas and immunostained with a guinea pig antiinsulin antibody (DAKO, Carpinteria, CA), a rabbit anti-glucagon antibody (DAKO), and a rabbit anti-PACAP antibody (Yanaihara Institute Inc., Shizuoka, Japan). Quantitative islet histomorphometry was performed as described previously with a few modifications (Masuzaki et al., 1999) . The whole pancreas was removed from sacrificed F 1 mice, and sections from each pancreas (representing the pancreatic head, body and tail) were obtained. Each section was stained with hematoxylin-eosin to obtain an enhanced view of the islets compared with the other areas of the pancreas. Total islet and pancreatic area were measured using a TE300 microscope (Nikon, 
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Tokyo, Japan) and Mac Scope image analysis software (Mitani Co., Fukui, Japan). Insulin Content in the Whole Pancreas. Each pancreas removed from a 28-week-old F 1 mouse was homogenized in 4 ml of ice-cold acid-ethanol solution (75% ethanol, 0.15 N HCl), and insulin was extracted for 48 h at 4°C. After centrifugation (2000 g; 30 min; 4°C), the supernatant was neutralized and diluted with PBS. The insulin concentrations in the 5000-fold diluted samples were assayed using the above-mentioned RIA kit.
Results
Overexpression of PACAP in Tg/؉ and Tg/؉:A y /؉ Mice. Genetic crosses between female Tg/ϩ mice and male A y /ϩ mice produced F 1 offspring with four genotypes (Tg/ϩ: A y /ϩ, Tg/ϩ, A y /ϩ, and ϩ/ϩ). Immunohistochemical staining for insulin and glucagon showed a normal distribution and topology of insulin-and glucagon-containing cells in F 1 mouse islets (Fig. 1, A-D) . In addition, there was no apparent difference in ␣-cell to ␤-cell ratio between Tg/ϩ:A y /ϩ and A y /ϩ mice, as well as between Tg/ϩ and ϩ/ϩ mice. PACAP immunoreactivity was weakly detected in the islets of ϩ/ϩ and A y /ϩ mice, whereas it was strongly detected throughout the islets of Tg/ϩ and Tg/ϩ:A y /ϩ mice ( Fig. 1, E-H) . A radioimmunoassay revealed that pancreatic PACAP content in Tg/ϩ mice was 141 Ϯ 18 pg/mg tissue, which was ϳ3-fold higher than that in ϩ/ϩ mice (48 Ϯ 12 pg/mg) (Fig. 1I) . Pancreatic PACAP content in A y /ϩ mice (38.3 Ϯ 1.2 pg/mg) was similar to that in ϩ/ϩ mice, whereas PACAP concentrations in Tg/ϩ:A y /ϩ mice (489 Ϯ 86 pg/mg) was ϳ13-fold higher than that in A y /ϩ mice (P Ͻ 0.001) and ϳ3.5-fold higher than that in Tg/ϩ mice (P Ͻ 0.01) (Fig. 1I) .
Body Weight Changes in F 1 Mice. The time course of changes in the body weight of 5-to 17-week-old F 1 mice was observed ( Fig. 2A) . By ϳ5 to 7 weeks of age, the four genotypes of mice had a similar body weight. Thereafter, the body weight of Tg/ϩ mice remained similar to that of ϩ/ϩ mice (at 17 weeks of age, 41.4 Ϯ 2.6 and 40.9 Ϯ 3.1 g, respectively). Tg/ϩ:A y /ϩ mice gradually developed obesity similar to that of A y /ϩ mice, and both genotypes remained obese compared with the lean mice (ϩ/ϩ and Tg/ϩ) (at 17 weeks of age, Tg/ϩ:A y /ϩ mice, 48.3 Ϯ 0.8 g; A y /ϩ mice, 52.6 Ϯ 1.0 g) (A y /ϩ versus ϩ/ϩ, P Ͻ 0.01; Tg/ϩ:A y /ϩ versus Tg/ϩ, P Ͻ 0.01). Plasma Insulin, Glucose, and Triglyceride Concentrations in F 1 Mice. The plasma insulin, glucose, and triglyceride concentrations were determined in F 1 mice in the fed state (Fig. 2, B-D) . From 8 weeks of age the plasma glucose and triglyceride levels in Tg/ϩ:A y /ϩ mice gradually increased in a similar manner to A y /ϩ mice, but remained virtually unchanged in ϩ/ϩ and Tg/ϩ mice (Fig. 2, C and D) . In A y /ϩ mice from 8 weeks old, the plasma insulin levels increased markedly and showed a dependence on age. Plasma insulin levels were also elevated in Tg/ϩ:A y /ϩ mice, but they were significantly decreased in Tg/ϩ:A y /ϩ mice by ϳ40 to 60% compared with A y /ϩ mice (P Ͻ 0.001, ANOVA; at 17 weeks of age, Tg/ϩ:A y /ϩ mice, 92 Ϯ 16 ng/ml; A y /ϩ mice, 233 Ϯ 14 ng/ml) (Fig. 2B) . The levels of plasma insulin in ϩ/ϩ and Tg/ϩ mice remained normal (at 17 weeks of age, ϩ/ϩ mice, 3.37 Ϯ 0.36; Tg/ϩ mice, 3.38 Ϯ 0.74 ng/ml).
Food Intake in F 1 Mice. For 2 weeks, the cumulative (ad libitum) food intake of F 1 mice was determined. Figure 3 shows total the food intake in F 1 animals between 15 and 17 weeks of age. There was no significant difference in the food intake between ϩ/ϩ and Tg/ϩ mice (4.64 Ϯ 0.18 and 4.48 Ϯ 0.12 g/day, respectively). The food intake in A y /ϩ mice (6.36 Ϯ 0.34 g/day) was 37% higher than that in ϩ/ϩ mice (P Ͻ 0.01). The food intake in Tg/ϩ:A y /ϩ mice (5.81 Ϯ 0.30 g/day) was not significantly different from that in A y /ϩ mice, but it was a significant 30% higher than in Tg/ϩ mice (P Ͻ 0.05). Similar results were obtained from animals between 5 and 7 weeks of age and between 21 and 23 weeks of age (data not shown).
Insulin Tolerance Test. The insulin tolerance test was performed to evaluate the insulin sensitivity of F 1 mice at between 21 and 30 weeks of age (Fig. 4) . No significant hypoglycemic effects were observed in A y /ϩ and Tg/ϩ:A y /ϩ mice when a normal dose of 0.5 U/kg insulin was administered (data not shown). A high dose of insulin (2 U/kg) was therefore chosen for the insulin tolerance test. Both ϩ/ϩ and 
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Tg/ϩ mice showed similar responses to an intraperitoneal injection of insulin (2 U/kg; P ϭ 0.48, ANOVA). The hypoglycemic response in Tg/ϩ:A y /ϩ mice was not significantly different from that in A y /ϩ mice (P ϭ 0.62, ANOVA), but throughout the observation period, plasma glucose levels in the obese (A y /ϩ and Tg/ϩ:A y /ϩ) mice were significantly higher compared with the lean (ϩ/ϩ and Tg/ϩ) mice (A y /ϩ versus ϩ/ϩ, P Ͻ 0.01; Tg/ϩ:A y /ϩ versus Tg/ϩ, P Ͻ 0.01, ANOVA). Similar results were obtained in mice at 8 weeks of age (data not shown).
Glucose Tolerance Test. An oral glucose tolerance test (2 mg/g body weight) revealed that after 30 min, plasma glucose concentrations were significantly lower in Tg/ϩ mice compared with the other genotypes (P Ͻ 0.05) (Fig. 5A) . Plasma glucose levels in the obese mice (A y /ϩ and Tg/ϩ:A y /ϩ) were significantly higher compared with the lean (ϩ/ϩ and Tg/ϩ) mice (A y /ϩ versus ϩ/ϩ, P Ͻ 0.05; Tg/ϩ:A y /ϩ versus Tg/ϩ, P Ͻ 0.01, ANOVA), but there was no difference between Tg/ϩ: A y /ϩ and A y /ϩ mice (P ϭ 0.63, ANOVA). In contrast, 10 min after glucose injection, plasma insulin levels were significantly higher in A y /ϩ mice compared with Tg/ϩ:A y /ϩ mice and the other genotypes (P Ͻ 0.001), but thereafter declined to similar levels found in Tg/ϩ:A y /ϩ mice (Fig. 5B) . Plasma insulin levels in the obese mice (A y /ϩ and 3 . Food intake in F 1 mice. Total food intake was measured in ϩ/ϩ (n ϭ 11), Tg/ϩ (n ϭ 10), A y /ϩ (n ϭ 15), and Tg/ϩ:A y /ϩ (n ϭ 17) mice during a 2-week period (between 15 and 17 weeks of age). Data are expressed as the mean Ϯ S.E. Statistically significant differences were assessed by ANOVA, followed by a post hoc Scheffé's test. 
Tg/ϩ:A y /ϩ) were again significantly higher compared with the lean mice (ϩ/ϩ and Tg/ϩ) (A y /ϩ versus ϩ/ϩ, P Ͻ 0.001; Tg/ϩ:A y /ϩ versus Tg/ϩ, P Ͻ 0.001, ANOVA). There was no significant difference between ϩ/ϩ and Tg/ϩ mice (P ϭ 0.75, ANOVA).
Histomorphometric Analysis of Pancreatic Islets in F 1 Mice. Histological examination of the pancreas of F 1 mice revealed that the islets of A y /ϩ mice showed marked hyperplasia compared with ϩ/ϩ mice (Fig. 6) . In contrast, the islets of Tg/ϩ:A y /ϩ mice were characterized by a smaller islet area compared with A y /ϩ mice. A systematic quantitative histomorphometric analysis of the pancreas of F 1 mice was then performed (Fig. 7) . The mean islet area in A y /ϩ mice (80,000 Ϯ 8,000 m 2 ) was significantly increased compared with ϩ/ϩ mice (21,900 Ϯ 2,300 m 2 ) (P Ͻ 0.001), but this increase was significantly attenuated in Tg/ϩ:A y /ϩ mice (49,500 Ϯ 5,200 m 2 ) (P Ͻ 0.01). The mean islet area in Tg/ϩ:A y /ϩ was significantly higher than that in Tg/ϩ mice (31,400 Ϯ 4,100 m 2 ) (P Ͻ 0.05) (Fig. 7A) . Although there was no significant difference in the number of islets per unit pancreas area between ϩ/ϩ, Tg/ϩ, and Tg/ϩ:A y /ϩ mice (0.337 Ϯ 0.34, 0.367 Ϯ 0.038, and 0.454 Ϯ 0.070 mm Ϫ2 , respectively), it was markedly increased in A y /ϩ mice (0.685 Ϯ 0.053 mm Ϫ2 ) compared with the three other genotypes (P Ͻ 0.01) (Fig. 7B ). The islet mass (which is the ratio of islet area to pancreatic area multiplied by the pancreatic wet weight) of A y /ϩ mice (40.9 Ϯ 6.2 mg/pancreas) was significantly greater compared with ϩ/ϩ and Tg/ϩ mice (ϩ/ϩ, 3.86 Ϯ 0.56 mg/pancreas, P Ͻ 0.001; Tg/ϩ, 6.23 Ϯ 0.79 mg/pancreas, P Ͻ 0.001). The islet mass in Tg/ϩ:A y /ϩ mice (19.4 Ϯ 2.9 mg/pancreas) was ϳ50% lower than that in A y /ϩ mice (P Ͻ 0.01) (Fig. 7C ). This result is in good agreement with the plasma insulin levels (Fig. 2B ) and pancreatic insulin content: the insulin content of the whole pancreas of Tg/ϩ:A y /ϩ mice was 61% lower than in A y /ϩ mice (5.4 Ϯ 1.7 and 13.7 Ϯ 3.7 g/g pancreas, respectively) (n ϭ 4). Finally, a reduction in islets size was caused by a decrease in the number of largest islets; the very large (Ͼ100,000 m 2 ) islets composing 26.2% of islets of A y /ϩ mice were selectively and significantly reduced in Tg/ϩ:A y /ϩ mice (14.2%; P Ͻ 0.05) (Fig. 7D) .
Discussion
The aim of the present study was to determine the effects of overexpressed PACAP in the pancreas on the development of type 2 diabetes, by examining the metabolic and morphological phenotypes of F 1 animals generated from genetic crosses of Tg/ϩ with A y /ϩ mice. Here, we show that 1) overexpression of PACAP does not influence the obesity phenotype (including hyperglycemia, hyperlipidemia, and hyperphagia) in A y /ϩ mice, but the hyperinsulinemia observed in A y /ϩ mice in the ad libitum-fed state was markedly ameliorated in Tg/ϩ:A y /ϩ mice (about 60% inhibition at 17 weeks of age); 2) plasma glucose levels in the fed state as well as during glucose and insulin tolerance testings were not different between A y /ϩ and Tg/ϩ:A y /ϩ mice; however, 3) an enhanced first-phase insulin response (0 -10 min) to a glucose load in A y /ϩ mice was significantly attenuated in Tg/ϩ:A y /ϩ mice; 4) although A y /ϩ mice exhibit a marked increase in islet mass resulting from islet hyperplasia and hypertrophy, this increase in islet mass was markedly reduced in Tg/ϩ: 
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A y /ϩ mice. It is noteworthy that 5) the very large islets (Ͼ100,000 m 2 ) composing one-fourth of islets of A y /ϩ mice were selectively and significantly reduced in Tg/ϩ:A y /ϩ mice. In the present study, immunohistochemical analysis indicated that endogenous PACAP expression in the islet ␤-cells of ϩ/ϩ and A y /ϩ mice is weak. As expected, Tg/ϩ and Tg/ϩ: A y /ϩ mice showed a marked increase in pancreatic PACAP content, and high levels of PACAP expression throughout the islets. A 3.5-fold increase in pancreatic PACAP content in Tg/ϩ:A y /ϩ compared with Tg/ϩ mice is in accordance with 3-fold elevation in the total islet mass in Tg/ϩ:A y /ϩ versus Tg/ϩ mice (Figs. 1I and 7C) .
However, irrespective of the genotypes, plasma PACAP levels were undetectable (Ͻ40 pg/ml) by RIA. Such a low level of plasma free PACAP is possibly due to the presence of the PACAP38-specific binding factor ceruloplasmin, whose physiological significance in PACAP-binding activity is currently unknown (Tams et al., 1999) .
Mice with the A y allele developed maturity-onset obesity and diabetes (hyperglycemia), but Tg/ϩ:A y /ϩ mice showed a blunted increase in plasma insulin levels. This finding is in contrast to previous results of ours obtained from Tg/ϩ mice (with a C57BL/6 genetic background), in which the insulin response to glucose was enhanced without affecting the plasma glucose response (Yamamoto et al., 2003) . The most plausible explanation for this discrepancy between the levels of insulin and glucose is an altered sensitivity to insulin due to changes in insulin resistance and/or glycogenolysis. However, our previous study with Tg/ϩ mice did not provide evidence to support these explanations. In the present study, insulin sensitivity, assessed by the insulin tolerance test after a 2-h fast, and fasting insulin levels after a 14-h fast (time 0 in Fig. 5B ) were unchanged between Tg/ϩ:A y /ϩ and A y /ϩ mice. However, the first-phase insulin response (10 min after glucose load) during the glucose tolerance test was higher in A y /ϩ mice than in Tg/ϩ:A y /ϩ mice. This occurred despite a similar plasma glucose response exhibited by these genotypes and may suggest an increased insulin resistance in A y /ϩ versus Tg/ϩ:A y /ϩ mice. It has been demonstrated that all three PACAP receptor types are found in adipose tissue (Wei and Mojsov, 1996) and that PACAP enhances insulin-induced glucose uptake in 3T3-L1 adipocytes (Nakata et al., 1999) . Given that PACAP overexpressed in Tg/ϩ:A y /ϩ mice is released from pancreatic islets into the circulation, whereas it may be bound to some plasma binding proteins (see above), it is likely that PACAP exerts an insulin-sensitizing effect through increased glucose uptake in adipose tissue. A more precise investigation of insulin sensitivity (e.g., insulin clamp technique) is clearly required.
The enlargement of pancreatic islets in various obese rodent models has been observed previously (Like and Chick, 1970; Chan et al., 1998) . To assess the impact of PACAP overexpression on islet morphology, we performed a histomorphometric analysis of the pancreas. As anticipated, A y /ϩ mice showed marked hyperplasia and hypertrophy, but Quantitative islet histomorphometry in F 1 mice. The mean of an islet area (A), the number of islets per square millimeter of total pancreatic area (B), total islet mass (C), and frequency distribution of islet areas (D) in F 1 mice. Data are expressed as the mean Ϯ S.E. Statistically significant differences were assessed by ANOVA, followed by a post hoc Fisher's protected least significant difference test.
PACAP Overexpression in A y Mouse Islets
PACAP overexpression significantly reduced the increases in mean islet area, the number of islets per pancreas area, and islet mass caused by the A y allele. The most striking finding was that very large islets observed in A y /ϩ mice were selectively reduced in Tg/ϩ:Ay/ϩ mice.
Previous morphological studies have shown that obese rodents have an increased proportion of very large islets (Chan et al., 1998) . In Zucker (fa/fa) rats, a widely used rodent model of type 2 diabetes characterized by obesity, hyperlipidemia, hyperinsulinemia, and islet hypertrophy, the large islets are inefficient releasers of insulin compared with small islets on the basis of mass (Hayek and Woodside, 1979) . Furthermore, large fa/fa islets have been shown to suffer multifocal to coalescing ␤-cell necrosis after overnight culture (Chan et al., 1998) . With these previous findings, the present results imply a regulatory effect of PACAP on the abnormal increase in islet mass that occurs during the diabetic process.
It has been demonstrated that PACAP acts as an intraislet autocrine/paracrine regulator of glucose-induced insulin secretion (Yada et al., 1997) . Such a loop is likely implicated in the action of overexpressed PACAP and may also be implicated in the regulation of ␤-cell growth and/or differentiation in normal animals.
PACAP, and related peptide GLP-1, stimulate insulin secretion in ␤-cells in a glucose-dependent manner, possibly via a similar signal transduction pathway (Leech et al., 1996) . GLP-1 stimulates the proliferation of INS-1 cells (Buteau et al., 1999) and increases the mass of ␤-cells in adult rodents in vivo, via both proliferation and neogenesis of ␤-cells (Kieffer and Habener, 1999) . However, there have been few investigations into the physiological roles of PACAP in pancreatic islets in vivo. In many cell types, PACAP is involved in a variety of cellular processes, including proliferation, differentiation, and cytoprotection (Arimura, 1998; Vaudry et al., 2000) , where the actions of PACAP are sometimes biphasic with stimulation occurring at lower doses (for instance, at subnanomolar concentrations), and inhibition at higher doses, or vice versa. PACAP stimulates several different signaling cascades, leading to the activation of adenylate cyclase, phospholipase C, extracellular regulated kinase, and also p38 mitogen-activated protein kinases (Arimura, 1998; Hashimoto et al., 2000; Vaudry et al., 2000; Sakai et al., 2001 Sakai et al., , 2002 . Future research should focus on the mechanisms underlying the PACAP-mediated regulation of ␤-cell fate and function.
